Offstream
news

---

Changes

1. The European Medicines Agency conditionally approves the use of the Pfizer's anti-COVID-19 oral drug Paxlovid for high-risk adult patients.
   2022-01-29 13:06:06 (First version)
2. The European Medicines Agency conditionally approves the use of the Pfizer anti-COVID-19 oral drug Paxlovid for high-risk adult patients.
   (Current version)

---

Related

Health Canada approves the use of Pfizer's anti-COVID-19 viral drug Paxlovid for people over the age of 18 years who are at risk of severe disease and death.
2022-01-17

Mexican health regulator COFEPRIS approves the emergency use of Pfizer's anti-COVID-19 oral drug Paxlovid.
2022-01-14

South Korea receives their first shipment of Pfizer's Paxlovid anti-COVID-19 oral drug.
2022-01-13

The Belgian government finalizes an agreement to buy 20,000 courses of Pfizer's Paxlovid COVID-19 drug and Merck & Co.'s Molnupiravir COVID-19 drug.
2022-01-3

The Medicines and Healthcare products Regulatory Agency approves the use of Pfizer's anti-viral oral drug Paxlovid for high-risk patients.
2021-12-31

South Korea authorizes the emergency use of the anti-viral oral drug Paxlovid manufactured by Pfizer for high-risk patients over the age of 12 years, becoming the first drug to be approved for use in the country.
2021-12-27

The Israeli government finalizes an agreement with Pfizer to purchase 100,000 courses of the anti-viral drug Paxlovid for high-risk patients over the age of 12 years, with delivery expected to begin in one week.
2021-12-25

The final results of a trial of Paxlovid conducted by Pfizer shows 89% cut of risk of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.
2021-12-14

A late-stage trial of the oral drug Paxlovid conducted by Pfizer shows an 89% reduction in hospitalizations and deaths.
2021-11-5

Pfizer and BioNTech announce that they will ask the European Medicines Agency to approve their potential vaccine candidate.
2020-12-1